Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ArQule has reported the enrollment and successful dosing of the first patient in a phase I clinical trial with the cancer therapy ARQ 171.
Subscribe to our email newsletter
ArQule also updated progress in its other clinical programs. These include three phase II trials with the first-generation E2F-1 compound, ARQ 501, as monotherapy in leiomyosarcoma and head and neck cancer, and as combination therapy with gemcitabine in pancreatic cancer, as well as a phase I trial with ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase. Swiss pharmaceutical company Roche has an option to ArQule's E2F-1 program in the field of cancer therapy.
The primary objective of the phase I trial is to determine the safety, tolerability and maximum tolerated dose of ARQ 171. Secondary objectives are to determine the pharmacokinetic profile and to assess the preliminary anti-tumor activity of the compound.